GlipiZIDE ER 2.5 mg Recall: Failed Dissolution Specs
Amerisource Health Services recalls GlipiZIDE ER 2.5 mg tablets due to failed dissolution specifications. Check lot numbers and expiration dates for affected units.
Use caution until it’s fixed
Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.
Contact the company
What happened, in plain English
Amerisource Health Services is recalling specific lots of GlipiZIDE Extended-release tablets, 2.5 mg, because they failed dissolution specifications. The recalled product exceeded the allowed dissolution rates at the 10-hour testing point. This means the medication may not release or work as intended for patients relying on it. Read more at govinfonow.com/recall/42052-glipizide-er-2-5-mg-recall-failed-dissolution-specs.
Source Summary by GovInfoNow · govinfonow.com/recall/42052-glipizide-er-2-5-mg-recall-failed-dissolution-specs · Updated October 11, 2026 · FDA enforcement record: FDA #D-0520-2017
Cite this page
“GlipiZIDE ER 2.5 mg Recall: Failed Dissolution Specs.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/42052-glipizide-er-2-5-mg-recall-failed-dissolution-specs. Based on FDA recall #D-0520-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0520-2017%22&limit=1).
Why it’s dangerous
The tablets failed to meet dissolution specifications at the 10-hour testing point, meaning they may not release the drug properly over time. For an extended-release medication, this failure could result in the patient receiving less medication than prescribed, potentially leading to inadequate blood sugar control.
Who’s affected
Patients who have been prescribed GlipiZIDE Extended-release tablets, 2.5 mg, by a healthcare provider and purchased them from pharmacies nationwide between the manufacturing dates and expiration dates listed below.
How to tell if you have this one
Check your medication bottle for the following details: Product name GlipiZIDE Extended-release tablets, strength 2.5 mg, 30-count carton. Look for NDC 68084-295-21 or Individual dose NDC 68084-395-11. Affected lot numbers are 160133 (Exp. 08/17), 160549 (Exp. 08/17), 162006 (Exp. 09/17), and 163348A or 163348B (Exp. 10/17).
- Brand
Amerisource Health Services- Category
Drug
What to do — step by step
Contact Your Pharmacist
Reach out to the pharmacy where you purchased the medication to determine if your specific lot is part of this recall.
Consult Your Doctor
Speak with your healthcare provider about whether you should continue taking the medication or switch to a different product while the recall is processed.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 13 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0520-2017 (February 3, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0520-2017 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.